Kaitlyn D’Onofrio

DocwireNews

Patients without<a href="https://proddocwire.wpengine.com/tag/cardiovascular-disease/"> cardiovascular disease</a> (CVD) may reduce their risk of cardiovascular events by taking <a href="https://proddocwire.wpengine.com/cardiology/rivaroxaban-not-superior-to-aspirin-for-preventing-stroke-after-embolic-stroke-of-unknown-origin/">aspirin</a>, but in doing so could put themselves at risk of internal bleeding, according to a new study.Researchers queried PubMed and Embase for randomized clinical trials including at least 1,000 patients without CVD who committed to at least 12 months of follow-up. Primary outcomes were cardiovascular (a composite of cardiovascular mortality, nonfatal myocardial infarction, and nonfatal stroke) and bleeding (any major bleeding as defined by the individual studies).<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
This meta-analysis confirms that use of <a href="https://twitter.com/hashtag/aspirin?src=hash&amp;ref_src=twsrc%5Etfw">#aspirin</a> for primary prevention of <a href="https://twitter.com/hashtag/cardiovasculardisease?src=hash&amp;ref_src=twsrc%5Etfw">#cardiovasculardisease</a> is associated with a lower risk of CV events including CV mortality and nonfatal AMI and <a href="https://twitter.com/hashtag/stroke?src=hash&amp;ref_src=twsrc%5Etfw">#stroke</a>, and an increased risk of major bleeding. <a href="https://t.co/waQWKhSEcX">https://t.co/waQWKhSEcX</a> <a href="https://t.co/PHH47WTA0m">pic.twitter.com/PHH47WTA0m</a>
&mdash; JAMA (@JAMA_current) <a href="https://twitter.com/JAMA_current/status/1087877579288297472?ref_src=twsrc%5Etfw">January 23, 2019</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>Final analysis included 13 trials with 164,225 total patients (mean age, 62 years; 53% female) and 1,050,511 patient-years of follow-up; 19% of patients had diabetes. Compared with no aspirin, patients taking aspirin had greatly reduced cardiovascular outcomes (57.1 per 10,000 patient-years with aspirin and 61.4 per 10,000 patient-years with no aspirin) (hazard ratio [HR], 0.89 [95% credible interval, 0.84-0.95]; absolute risk reduction, 0.38% [95% CI, 0.20%-0.55%]; number needed to treat, 265). However, patients using aspirin also had greater incidence of major bleeding events (23.1 per 10&#8239;000 participant-years with aspirin and 16.4 per 10&#8239;000 participant-years with no aspirin) (HR, 1.43 [95% credible interval, 1.30-1.56]; absolute risk increase, 0.47% [95% CI, 0.34%-0.62%]; number needed to harm, 210).<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
A daily aspirin is often recommended for people with heart trouble; is it actually beneficial? Experts, including Donna Arnett, our dean of <a href="https://twitter.com/UKCPH?ref_src=twsrc%5Etfw">@UKCPH</a> and past president of <a href="https://twitter.com/American_Heart?ref_src=twsrc%5Etfw">@American_Heart</a> , talk to <a href="https://twitter.com/CNN?ref_src=twsrc%5Etfw">@CNN</a> about the benefits &ndash; and risks.<a href="https://t.co/5Y7tu4FJ37">https://t.co/5Y7tu4FJ37</a>
&mdash; UK_GillHeart (@GillKentucky) <a href="https://twitter.com/GillKentucky/status/1088454203767308290?ref_src=twsrc%5Etfw">January 24, 2019</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
What is the association of aspirin use with CV &amp; bleeding events in individuals free of <a href="https://twitter.com/hashtag/CVD?src=hash&amp;ref_src=twsrc%5Etfw">#CVD</a>? Find out in this journal scan: <a href="https://t.co/DwyTTLQ32S">https://t.co/DwyTTLQ32S</a> <a href="https://twitter.com/hashtag/cvPrev?src=hash&amp;ref_src=twsrc%5Etfw">#cvPrev</a>
&mdash; American College of Cardiology (@ACCinTouch) <a href="https://twitter.com/ACCinTouch/status/1088490365114597377?ref_src=twsrc%5Etfw">January 24, 2019</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>One of the study&rsquo;s limitations pertained to the diabetes subgroup, for which cardiovascular and bleeding outcomes were poorly reported. Another was that each study did not have the exact same primary outcome. Additionally, daily aspirin doses varied in each study, from 50 mg to 500 mg. Finally, some studies began as early as the 1970s, while some started after 2000. &ldquo;Increasing adoption of additional primary prevention strategies, such as risk factor modification and development of public health initiatives, may limit the applicability of earlier studies to current practice,&rdquo; the researchers noted.<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Aspirin can cause unnecessary and dangerous bleeding when taken regularly by those with no history of coronary artery disease&hellip;. <a href="https://t.co/C3jXdNvj7Y">https://t.co/C3jXdNvj7Y</a>
&mdash; James Kneller, MD, PhD, FHRS (@JamesKnellerMD) <a href="https://twitter.com/JamesKnellerMD/status/1088120931262910464?ref_src=twsrc%5Etfw">January 23, 2019</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>Still, the study authors concluded that their findings &ldquo;may inform discussions with patients about aspirin for primary prevention of cardiovascular events and bleeding.&rdquo;<a href="https://proddocwire.wpengine.com/docwire-pick/aspirin-reduce-cv-risk/">ASPREE: Primary Prevention with Low-dose Aspirin Doesn&rsquo;t Reduce CV Risk</a><a href="https://proddocwire.wpengine.com/docwire-pick/cardiology-picks/analysis-one-dose-fits-all-aspirin-regimen-not-optimal-for-all-patients/">Analysis: One-dose-fits-all Aspirin Regimen Not Optimal for All Patients</a><a href="https://proddocwire.wpengine.com/abstracts/aspirin-venous-thromboembolism-patients/">Association of Aspirin With Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty Compared With Other Anticoagulants: A Noninferiority Analysis</a><a href="https://proddocwire.wpengine.com/neurology/efficacy-and-safety-of-ticagrelor-in-relation-to-aspirin-use-within-the-week-before-randomization-in-the-socrates-trial-original-contributions/">Efficacy and Safety of Ticagrelor in Relation to Aspirin Use Within the Week Before Randomization in the SOCRATES Trial [Original Contributions]</a>Source: <a href="https://jamanetwork.com/journals/jama/fullarticle/2721178?guestAccessKey=b6c6e6e2-80a8-449e-9278-a863ceaa9c67">JAMA</a>

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Aspirin May Increase Internal Bleeding Risk

Cardiology

Patients without cardiovascular disease (CVD) may reduce their risk of cardiovascular events by taking aspirin, but in doing so could put themselves at risk of internal ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe